anti-inflammatoty and immuno-therapy - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.88 [0.82, 0.94]< 127%61 studies (61/-)100.0 %some concerncritical moderatecrucial-
death or transfer to ICU 0.79 [0.50, 1.24]< 10%2 studies (2/-)84.9 %some concernnot evaluable moderatecrucial-
deaths 0.89 [0.85, 0.93]< 122%102 studies (102/-)100.0 %some concerncritical moderatecrucial1
deaths (time to event analysis only) 0.81 [0.69, 0.94]< 131%15 studies (15/-)99.7 %some concernlow moderatecrucial-
clinical deterioration 0.71 [0.58, 0.86]< 149%21 studies (21/-)100.0 %some concernlow moderateimportant-
clinical improvement 1.15 [1.06, 1.26]> 139%29 studies (29/-)100.0 %some concerncritical moderateimportant-
clinical improvement (14-day) 1.31 [1.06, 1.62]> 142%9 studies (9/-)99.3 %some concernserious moderateimportant-
clinical improvement (28-day) 1.53 [1.09, 2.14]> 149%10 studies (10/-)99.3 %some concerncritical moderateimportant-
clinical improvement (7-day) 1.29 [0.82, 2.01]> 161%5 studies (5/-)86.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.11 [1.01, 1.22]> 120%13 studies (13/-)98.9 %some concerncritical moderateimportant-
death or ventilation 0.90 [0.85, 0.96]< 157%24 studies (24/-)100.0 %some concerncritical moderateimportant-
hospital discharge 1.07 [1.00, 1.15]> 163%12 studies (12/-)97.1 %some concerncritical moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.90 [0.82, 0.98]< 115%28 studies (28/-)99.4 %some concerncritical moderateimportant1
radiologic improvement (14-day) 3.02 [1.77, 5.14]> 10%3 studies (3/-)100.0 %some concernnot evaluable moderateimportant-
viral clearance